<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel rdf:about="https://scholar.dgist.ac.kr/handle/20.500.11750/173">
    <title>Repository Collection: null</title>
    <link>https://scholar.dgist.ac.kr/handle/20.500.11750/173</link>
    <description />
    <items>
      <rdf:Seq>
        <rdf:li rdf:resource="https://scholar.dgist.ac.kr/handle/20.500.11750/60611" />
        <rdf:li rdf:resource="https://scholar.dgist.ac.kr/handle/20.500.11750/60229" />
        <rdf:li rdf:resource="https://scholar.dgist.ac.kr/handle/20.500.11750/60217" />
        <rdf:li rdf:resource="https://scholar.dgist.ac.kr/handle/20.500.11750/59929" />
      </rdf:Seq>
    </items>
    <dc:date>2026-08-23T22:32:49Z</dc:date>
  </channel>
  <item rdf:about="https://scholar.dgist.ac.kr/handle/20.500.11750/60611">
    <title>96-Well Format-Based Liver–Heart-on-a-Chip Platform for Facile and Parallel Testing of Drug-Induced Cardiotoxicity after Liver Metabolism</title>
    <link>https://scholar.dgist.ac.kr/handle/20.500.11750/60611</link>
    <description>Title: 96-Well Format-Based Liver–Heart-on-a-Chip Platform for Facile and Parallel Testing of Drug-Induced Cardiotoxicity after Liver Metabolism
Author(s): Lee, Sebeen; Jin, Chaewon; Choi, Hongsoo; Kim, Jin-young
Abstract: Current preclinical drug evaluation predominantly relies on conventional two-dimensional (2D) cell cultures grown in static environments, which lack dynamic interactions and fail to recapitulate complex microenvironments. These approaches are inefficient and overly simplistic, and often require costly animal models that poorly mimic human physiology. Body-on-a-chip (BoC) technology─comprising robust and flexible three-dimensional (3D) microtissues (MTs)─has emerged to address these limitations. BoC platforms constitute microphysiological systems that mimic human organ physiology and function in vitro, enabling improved toxicity screening and personalized medicine. Here, we present a 96–well format-based microfluidic liver–heart-on-a-chip platform that supports parallel, gravity-driven perfusion to efficiently predict and assess multiorgan drug effects. We demonstrate hepatic metabolism of the cardiotoxic prodrug terfenadine (TFND) into its noncardiotoxic metabolite fexofenadine within liver MTs and the consequent physiological–pathological responses of cardiac MTs. The optimized liver–heart-on-a-chip preserves multitissue functionality, underscores the importance of continuous media circulation, and reveals intertissue interactions relevant to drug-induced cardiotoxicity after liver metabolism.</description>
    <dc:date>2026-02-28T15:00:00Z</dc:date>
  </item>
  <item rdf:about="https://scholar.dgist.ac.kr/handle/20.500.11750/60229">
    <title>A magnetically steerable soft gripper for navigating and grasping in constrained spaces</title>
    <link>https://scholar.dgist.ac.kr/handle/20.500.11750/60229</link>
    <description>Title: A magnetically steerable soft gripper for navigating and grasping in constrained spaces
Author(s): Dong Xiao; Lee, Hakjoon; Ahmed, Awais; Choi, Hongsoo
Abstract: Magnetic soft grippers hold significant promise for applications requiring gentle and soft interaction with objects. However, steering their movement within constrained spaces remains a major challenge. This study presents a magnetically steerable soft gripper that combines a magnetically steerable soft tube with a magnetic soft gripper. By utilizing distinct magnetization directions for the soft gripper and soft tube, both steering and gripping can be achieved through an external magnetic field. The gripper is capable of lifting objects weighing more than 68 times its own weight under a 40 mT magnetic field (1.7 times per mT). It can also grasp objects of various shapes and sizes. When integrated with a commercial catheter, the steerable gripper successfully performs targeted gripping in a 3D phantom environment. This work introduces a novel magnetically steerable soft gripper system for precise manipulation in confined spaces, with strong potential for applications inside the human body. © The Korean Society of Mechanical Engineers and Springer-Verlag GmbH Germany, part of Springer Nature 2026.</description>
    <dc:date>2025-12-31T15:00:00Z</dc:date>
  </item>
  <item rdf:about="https://scholar.dgist.ac.kr/handle/20.500.11750/60217">
    <title>Magnetic hyperthermia-induced hydrogen therapy for cancer treatment using PEG-coated Mg–Ni Degradable microrobots</title>
    <link>https://scholar.dgist.ac.kr/handle/20.500.11750/60217</link>
    <description>Title: Magnetic hyperthermia-induced hydrogen therapy for cancer treatment using PEG-coated Mg–Ni Degradable microrobots
Author(s): Dutta, Sourav; Patra, Tanushree; Yea, Kyungmoo; Choi, Hongsoo
Abstract: Hydrogen therapy using magnesium-based micromotors offers a promising strategy for treating diseases such as cancer, diabetes, and Alzheimer’s, which are associated with elevated levels of reactive oxygen species (ROS). However, their clinical application is limited by uncontrollable motion and high reactivity in physiological environments. To overcome these challenges, we have developed a polymer-coated, magnetically guided magnesium (Mg) microrobot that integrates hydrogen therapy with magnetic hyperthermia. The polymer coating ensures stability in phosphate-buffered saline (PBS), while the microrobot achieves a velocity of 18.63 ± 0.85 μm/s under a 15 mT, 10 Hz rotating magnetic field. Mild magnetic heating (∼43 °C) partially melts the polymeric shell, triggering hydrogen release. In vitro studies with HCT 116 cells demonstrated a significant reduction in ROS at 3 mg/mL following magnetic hyperthermia. In vivo experiments in mice showed that the microrobot alleviated oxidative stress and significantly decreased tumor volume. These results indicated that Mg-based microrobots represent a controllable and effective therapeutic platform for ROS-related diseases. © 2026 .</description>
    <dc:date>2026-01-31T15:00:00Z</dc:date>
  </item>
  <item rdf:about="https://scholar.dgist.ac.kr/handle/20.500.11750/59929">
    <title>Translational reprogramming of dentate gyrus peptidergic circuitry gates antidepressant efficacy</title>
    <link>https://scholar.dgist.ac.kr/handle/20.500.11750/59929</link>
    <description>Title: Translational reprogramming of dentate gyrus peptidergic circuitry gates antidepressant efficacy
Author(s): Oh, Seo-Jin; Jang, Jin-Hyeok; Roussarie, Jean-Pierre; Jang, Kyung-un; Jeong, Min-Seok; Jo, Yeon Suk; Shin, Chang Hun; Choi, Hongsoo; Lee, Kwang; Yoon, Jong-Hyeok; Oh, Yong-Seok
Abstract: Selective serotonin reuptake inhibitors (SSRIs) exhibit delayed therapeutic effects despite rapid serotonin elevation, suggesting their dependence on slow neuroplastic adaptations. Here, we demonstrate that antidepressant actions require cell type-specific translational regulation of the peptidergic signaling in the dentate gyrus (DG). Chronic, but not acute, treatment with an SSRI fluoxetine (FLX) selectively enhances translational activity in hilar mossy cells (MCs), with no detectable changes in neighboring granule cells (GCs). Combining Translating Ribosome Affinity Purification (TRAP) with RNA sequencing revealed distinct baseline translatomes between these two glutamatergic neurons and identified FLX-induced remodeling of peptidergic pathways in the DG. Crucially, we discovered MC-specific enrichment of the neuropeptide PACAP, which undergoes translation-dependent upregulation by chronic FLX treatment. This PACAP induction mediates neuroadaptive plasticity in PAC1 receptor-expressing GCs and drives behavioral responses prominently in female mice during prolonged FLX administration. Our findings establish cell type-specific translational reprogramming as a novel mechanistic framework for antidepressant action.</description>
    <dc:date>2026-01-31T15:00:00Z</dc:date>
  </item>
</rdf:RDF>

